Will Pickering: FDA Under Trump, A New Era of Regulation

About this episode

Will Pickering discusses the complexities and challenges facing the US biotech market and FDA inspection trends under the Trump administration.

In this episode of In the Know, US Biotech Analyst Will Pickering joins host Diana Wood to discuss the current state of the US biotech market, and the complexities and challenges facing this industry today. Here, they explore FDA inspection trends, both long-term and under the Trump administration, with insights into the sector’s recovery, the impact of FDA headcount reductions, the potential consequences of inspection outcomes on drug approvals, and much more.   This podcast was recorded on Jan 29, 2026. Since then, turmoil at FDA has only increased, culminating in the recent resignation of CBER Director Vinay Prasad. While that particular drama has now played out, the broader issues Will highlights in this podcast are sure to remain relevant in the months and years ahead. Hosted on Acast. See acast.com/privacy for more information.

People in this episode

Host: Diana Wood

Guest: Will Pickering

Topics covered

• biotech market
• FDA regulation
• drug approvals
• inspection trends
• Trump administration
• industry challenges

Keywords

• biotech
• FDA
• drug approvals
• inspection trends
• Trump administration
• industry challenges
• Vinay Prasad

Mentioned in this episode

Organizations: FDA, CBER

Places: US

More episodes of In the Know

• Nadine Sarwat: A $20+ Cocktail... In This Economy? · June 3, 2026 · 31 min
• Annick Maas: Concert Tickets, Who Really Sets the Price? · May 19, 2026 · 26 min
• Courtney Breen: GLP-1s & the Oral Obesity Era · May 5, 2026 · 36 min
• Harshita Rawat: Visa, The Next Decade of Growth · April 22, 2026 · 34 min
• Rupal Agarwal: Gen AI in Asset Management · April 1, 2026 · 31 min
• Jay Huang: The Dawn of the Next Robot Age · March 17, 2026 · 26 min